Corrigendum: sARC018_SPORE02: Phase II study of mocetinostat administered with gemcitabine for patients with metastatic leiomyosarcoma with progression or relapse following prior treatment with gemcitabine-containing therapy (Sarcoma (2018) 2018 (2068517) DOI: 10.1155/2018/2068517)

Edwin Choy, Karla Ballman, James Chen, Mark A. Dickson, Rashmi Chugh, Suzanne George, Scott Heitaka Okuno, Raphael Pollock, Rajiv M. Patel, Antje Hoering, Shreyaskumar Patel

Research output: Contribution to journalComment/debate

Abstract

In the article titled "SARC018_SPORE02: Phase II Study of Mocetinostat Administered with Gemcitabine for Patients with Metastatic Leiomyosarcoma with Progression or Relapse following Prior Treatment with Gemcitabine-Containing Therapy" [1], the second author, Dr. Ballman, was paid by Lilly and only recently realized that gemcitabine is a Lilly product and apologizes for not declaring this sooner.

Original languageEnglish (US)
Article number7608743
JournalSarcoma
Volume2019
DOIs
StatePublished - Jan 1 2019

Fingerprint

gemcitabine
Leiomyosarcoma
Sarcoma
Recurrence
Therapeutics
mocetinostat
corrigendum

ASJC Scopus subject areas

  • Oncology
  • Radiology Nuclear Medicine and imaging

Cite this

Corrigendum : sARC018_SPORE02: Phase II study of mocetinostat administered with gemcitabine for patients with metastatic leiomyosarcoma with progression or relapse following prior treatment with gemcitabine-containing therapy (Sarcoma (2018) 2018 (2068517) DOI: 10.1155/2018/2068517). / Choy, Edwin; Ballman, Karla; Chen, James; Dickson, Mark A.; Chugh, Rashmi; George, Suzanne; Okuno, Scott Heitaka; Pollock, Raphael; Patel, Rajiv M.; Hoering, Antje; Patel, Shreyaskumar.

In: Sarcoma, Vol. 2019, 7608743, 01.01.2019.

Research output: Contribution to journalComment/debate

@article{a10712b9f4fe40f7a9572ec647bd7ab1,
title = "Corrigendum: sARC018_SPORE02: Phase II study of mocetinostat administered with gemcitabine for patients with metastatic leiomyosarcoma with progression or relapse following prior treatment with gemcitabine-containing therapy (Sarcoma (2018) 2018 (2068517) DOI: 10.1155/2018/2068517)",
abstract = "In the article titled {"}SARC018_SPORE02: Phase II Study of Mocetinostat Administered with Gemcitabine for Patients with Metastatic Leiomyosarcoma with Progression or Relapse following Prior Treatment with Gemcitabine-Containing Therapy{"} [1], the second author, Dr. Ballman, was paid by Lilly and only recently realized that gemcitabine is a Lilly product and apologizes for not declaring this sooner.",
author = "Edwin Choy and Karla Ballman and James Chen and Dickson, {Mark A.} and Rashmi Chugh and Suzanne George and Okuno, {Scott Heitaka} and Raphael Pollock and Patel, {Rajiv M.} and Antje Hoering and Shreyaskumar Patel",
year = "2019",
month = "1",
day = "1",
doi = "10.1155/2019/7608743",
language = "English (US)",
volume = "2019",
journal = "Sarcoma",
issn = "1357-714X",
publisher = "Hindawi Publishing Corporation",

}

TY - JOUR

T1 - Corrigendum

T2 - sARC018_SPORE02: Phase II study of mocetinostat administered with gemcitabine for patients with metastatic leiomyosarcoma with progression or relapse following prior treatment with gemcitabine-containing therapy (Sarcoma (2018) 2018 (2068517) DOI: 10.1155/2018/2068517)

AU - Choy, Edwin

AU - Ballman, Karla

AU - Chen, James

AU - Dickson, Mark A.

AU - Chugh, Rashmi

AU - George, Suzanne

AU - Okuno, Scott Heitaka

AU - Pollock, Raphael

AU - Patel, Rajiv M.

AU - Hoering, Antje

AU - Patel, Shreyaskumar

PY - 2019/1/1

Y1 - 2019/1/1

N2 - In the article titled "SARC018_SPORE02: Phase II Study of Mocetinostat Administered with Gemcitabine for Patients with Metastatic Leiomyosarcoma with Progression or Relapse following Prior Treatment with Gemcitabine-Containing Therapy" [1], the second author, Dr. Ballman, was paid by Lilly and only recently realized that gemcitabine is a Lilly product and apologizes for not declaring this sooner.

AB - In the article titled "SARC018_SPORE02: Phase II Study of Mocetinostat Administered with Gemcitabine for Patients with Metastatic Leiomyosarcoma with Progression or Relapse following Prior Treatment with Gemcitabine-Containing Therapy" [1], the second author, Dr. Ballman, was paid by Lilly and only recently realized that gemcitabine is a Lilly product and apologizes for not declaring this sooner.

UR - http://www.scopus.com/inward/record.url?scp=85072381260&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85072381260&partnerID=8YFLogxK

U2 - 10.1155/2019/7608743

DO - 10.1155/2019/7608743

M3 - Comment/debate

AN - SCOPUS:85072381260

VL - 2019

JO - Sarcoma

JF - Sarcoma

SN - 1357-714X

M1 - 7608743

ER -